InsiderTrades

Form 4 for IDXX Idexx Laboratories

Accepted 2025-05-08 00:00:00 ET · period of report 2025-05-06 · accession 0000874716-25-000078 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-05-08 2025-05-06 IDXX ESSIG STUART Dir M - OptEx $0.00 +262 2,236 +13% $0
D 2025-05-08 2025-05-06 IDXX ESSIG STUART Dir M - OptEx $0.00 -262 0 -100% $0
DM 2025-05-08 2025-05-07 IDXX ESSIG STUART Dir A - Grant $0.00 +857 600 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-05-06 M A 262 $0.00 2,236 D — —
2 Derivative Restricted Stock Unit 2025-05-06 M D 262 $0.00 0 D — · — to — 262 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier.
3 Derivative Deferred Stock Unit 2025-05-07 A A 257 $0.00 257 D — · — to — 257 Common Stock (F3) Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.
4 Derivative Non-Qualified Stock Option (right-to-buy) 2025-05-07 A A 600 $0.00 600 D $486.61 · — to 2035-05-06 600 Common Stock (F2) Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier.